Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $53.74 USD
Change Today +0.73 / 1.38%
Volume 768.5K
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

chimerix inc (CMRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - $54.95
52 Week Low
08/7/14 - $22.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHIMERIX INC (CMRX)

chimerix inc (CMRX) Related Businessweek News

View More BusinessWeek News

chimerix inc (CMRX) Details

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds include brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, as well as to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections. Its preclinical testing product includes CMX669 for the treatment of BK virus and CMV. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for certain antiviral indications; and BARDA to develop brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

83 Employees
Last Reported Date: 05/11/15
Founded in 2000

chimerix inc (CMRX) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $419.3K
Chief Commercial Officer
Total Annual Compensation: $333.6K
Chief Medical Officer
Total Annual Compensation: $128.5K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2014.

chimerix inc (CMRX) Key Developments

Chimerix Seeks Acquisitions

Chimerix, Inc. (NasdaqGM:CMRX) has filed a Follow-on Equity Offering in the amount of $150.00 million, Chimerix will retain broad discretion over the use of the net proceeds from the sale of our common stock hereby. Unless otherwise indicated in any prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you, we intend to use the net proceeds from the sale of our common stock under this prospectus for general corporate purposes, which may include clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our business, although we have no present commitments or agreements to make any such acquisitions or investments.

Chimerix, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Chimerix, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenues were $1,238,000 against $780,000 a year ago. Revenues increased due to an increase in the first quarter of 2015 in reimbursable expenses associated with the company's ongoing development contract with BARDA. Loss from operations was $22,329,000 against $10,184,000 a year ago. The variance was primarily due to the increased research and development, and general and administrative expenses, as previously discussed. Net loss was $22,266,000 against $10,380,000 a year ago. Net loss per common share, basic & diluted was $0.54 against $0.39 a year ago.

Chimerix, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 03:00 PM

Chimerix, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 03:00 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: William Garrett Nichols, Chief Medical Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMRX:US $53.74 USD +0.73

CMRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr306.50 DKK -14.50
Bioporto A/S kr2.54 DKK +0.02
Emergent BioSolutions Inc $32.83 USD +0.07
GlaxoSmithKline PLC 1,396 GBp -0.50
PharmAthene Inc $1.69 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CMRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 492.5x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 499.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHIMERIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at